JP2002513019A - パロキセチン・アスコルビン酸塩 - Google Patents

パロキセチン・アスコルビン酸塩

Info

Publication number
JP2002513019A
JP2002513019A JP2000545858A JP2000545858A JP2002513019A JP 2002513019 A JP2002513019 A JP 2002513019A JP 2000545858 A JP2000545858 A JP 2000545858A JP 2000545858 A JP2000545858 A JP 2000545858A JP 2002513019 A JP2002513019 A JP 2002513019A
Authority
JP
Japan
Prior art keywords
paroxetine
present
ascorbate
solution
paroxetine ascorbate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000545858A
Other languages
English (en)
Japanese (ja)
Inventor
マイケル・アーカート
Original Assignee
スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー filed Critical スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー
Publication of JP2002513019A publication Critical patent/JP2002513019A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2000545858A 1998-04-25 1999-04-23 パロキセチン・アスコルビン酸塩 Pending JP2002513019A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9808896.6 1998-04-25
GBGB9808896.6A GB9808896D0 (en) 1998-04-25 1998-04-25 Novel compound
PCT/GB1999/001244 WO1999055698A1 (en) 1998-04-25 1999-04-23 Paroxetine ascorbate

Publications (1)

Publication Number Publication Date
JP2002513019A true JP2002513019A (ja) 2002-05-08

Family

ID=10831008

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000545858A Pending JP2002513019A (ja) 1998-04-25 1999-04-23 パロキセチン・アスコルビン酸塩

Country Status (20)

Country Link
EP (1) EP1089995A1 (xx)
JP (1) JP2002513019A (xx)
KR (1) KR20010042977A (xx)
CN (1) CN1297448A (xx)
AP (1) AP2000001963A0 (xx)
AU (1) AU3618499A (xx)
BG (1) BG104940A (xx)
BR (1) BR9909868A (xx)
CA (1) CA2330055A1 (xx)
EA (1) EA200001104A1 (xx)
GB (1) GB9808896D0 (xx)
HU (1) HUP0102116A3 (xx)
ID (2) ID26654A (xx)
IL (1) IL139081A0 (xx)
NO (1) NO20005352L (xx)
PL (1) PL343677A1 (xx)
SK (1) SK15912000A3 (xx)
TR (1) TR200003084T2 (xx)
WO (1) WO1999055698A1 (xx)
ZA (1) ZA200005912B (xx)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005520803A (ja) * 2002-01-09 2005-07-14 エミスフェアー・テクノロジーズ・インク ４−［（４−クロロ−２−ヒドロキシベンゾイル）アミノ］ブタン酸ナトリウムの多形体

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
IL159280A0 (en) * 2001-06-14 2004-06-01 Teva Pharma A process for preparing paroxetine hcl which limits formation of pink colored compounds
CN110607554B (zh) * 2018-10-30 2024-03-22 中国科学院化学研究所 一种制备药物或药物中间体单晶或无定型物的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
EP0223403B1 (en) * 1985-10-25 1993-08-04 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament
US5276042A (en) * 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
ES2117557B1 (es) * 1996-02-29 1999-07-01 Ferrer Int Nuevo procedimiento de obtencion de (-)-trans -n-p-fluorobenzoilmetil-4-(p-fluorofenil)-3- ((3,4-(metilendioxi)fenoxi ) metil)-piperidina.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005520803A (ja) * 2002-01-09 2005-07-14 エミスフェアー・テクノロジーズ・インク ４−［（４−クロロ−２−ヒドロキシベンゾイル）アミノ］ブタン酸ナトリウムの多形体
US7893297B2 (en) 2002-01-09 2011-02-22 Emisphere Technologies, Inc. Amorphous sodium 4-[4-chloro-2-hydroxybenzoyl)amino]butanoate

Also Published As

Publication number Publication date
PL343677A1 (en) 2001-08-27
BR9909868A (pt) 2000-12-19
NO20005352D0 (no) 2000-10-24
SK15912000A3 (sk) 2001-04-09
TR200003084T2 (tr) 2001-02-21
AP2000001963A0 (en) 2000-12-31
CN1297448A (zh) 2001-05-30
ZA200005912B (en) 2001-12-19
NO20005352L (no) 2000-10-24
WO1999055698A1 (en) 1999-11-04
ID26654A (id) 2001-01-25
HUP0102116A2 (hu) 2002-05-29
KR20010042977A (ko) 2001-05-25
EP1089995A1 (en) 2001-04-11
AU3618499A (en) 1999-11-16
HUP0102116A3 (en) 2002-12-28
IL139081A0 (en) 2001-11-25
BG104940A (bg) 2001-09-28
GB9808896D0 (en) 1998-06-24
EA200001104A1 (ru) 2001-04-23
ID26083A (id) 2000-11-23
CA2330055A1 (en) 1999-11-04

Similar Documents

Publication Publication Date Title
DE60018040T2 (de) Polymorphische kristalline formen von celecoxib
EP1414454A1 (en) Paroxetine glycyrrhizinate
KR20060135866A (ko) 바제독시펜 아세테이트의 결정질 다형체
JP2007532548A (ja) バゼドキシフェンアセテートの結晶質多形体
JP3518601B2 (ja) エバスタイムまたはその類似体に基づく医薬組成物
EP1844017A1 (en) An amorphous and three crystalline forms of rimonabant hydrochloride
JP2002505254A (ja) パロキセチン塩
JP2002513019A (ja) パロキセチン・アスコルビン酸塩
JP2003527424A (ja) オキサゾリジノン錠剤製剤
JP2002511466A (ja) マレイン酸パロキセチン
JP2002513020A (ja) Ｃｎｓ疾患治療のための１０−ショウノウスルホン酸パロキセチン
MXPA00010439A (en) Paroxetine ascorbate
MXPA00010435A (en) Paroxetine 10-camphorsulfonate for treatment of cns disorders
JP2951410B2 (ja) 結晶（―）―３ｒ，４ｒ―トランス―７―メトキシ―２，２―ジメチル―３―フェニル―４―｛４―〔２―（ピロリジン―１―イル）エトキシ〕フェニル｝クロマン・酸性フマル酸塩
CZ20003942A3 (cs) Askorbat paroxetinu
JP2002531453A (ja) パロキセチン塩酸塩アセトン溶媒和物の製法
WO2001014369A2 (en) Process for the preparation of paroxetin.hcl
CZ20003722A3 (cs) Maleat paroxetinu
AU2528899A (en) Salts of paroxetine
CZ20003941A3 (cs) 10-KafrsuIfonat paroxetinu pro léčbu poruch centrálního nervového systému
MXPA00009884A (en) Paroxetine maleate
JP2002516611A (ja) 結晶性（−）−３ｒ，４ｒ−トランス−７−メトキシ−２，２−ジメチル−３−フェニル−４−｛４−〔２−（ピロリジン−１−イル）エトキシ〕フェニル｝クロマン水素マレエート
MXPA06011717A (en) Crystalline polymorph of bazedoxifene acetate
CZ20002845A3 (cs) Soli paroxetinu